Sanofi FR Stock Price, News & Analysis

EVOQ Therapeutics announced a Collaboration and License Agreement with Sanofi (NASDAQ: SNY) on October 16, 2025 to advance EVOQ's NanoDisc technology for autoimmune diseases. Under the deal, Sanofi will lead development and worldwide commercialization while EVOQ is eligible to receive over $500 million in upfront, preclinical, development and sales milestones plus tiered royalties on product sales. The NanoDisc platform aims to restore immune tolerance across indications including celiac disease, type 1 diabetes, MOG antibody disease, rheumatoid arthritis and lupus.

The agreement pairs EVOQ's proprietary platform with Sanofi's immunology and commercial capabilities, transferring development and market responsibilities to Sanofi and establishing milestone-driven payments and royalty economics for EVOQ.

Revvity (NYSE:RVTY) has announced a significant program to expand its type 1 diabetes (T1D) testing capabilities, partnering with Sanofi. The initiative includes developing a T1D 4-plex in vitro diagnostic (IVD) assay based on their existing 3-plex research-use assay.

The program aims to enable population-scale screening for early-stage T1D using Revvity's GSP® instrument with both capillary dried blood spot and venous specimens. The company plans regulatory submissions to the U.S. FDA, IVDR, and other major jurisdictions. Additionally, Revvity will expand its laboratory network globally to increase access to its existing research-use product, currently offered as an LDT at their CLIA and CAP accredited Revvity Omics laboratory in Pittsburgh.

This initiative addresses a significant medical need, as over 9 million people worldwide live with T1D, with more than 500,000 new cases diagnosed annually, 90% without family history.

Sanofi (NASDAQ:SNY) has announced a significant expansion of its Insulins Valyou Savings Program, offering all Americans access to any Sanofi insulin for $35 per month, regardless of their insurance status. The expanded program, effective January 1, 2026, will be available to patients with commercial insurance, Medicare, or no insurance.

The initiative will cover all Sanofi insulins at most pharmacies across the US, including independent and rural locations. Patients can obtain any combination, type, and quantity of Sanofi insulins with a valid prescription at this fixed monthly price. The program aims to eliminate financial barriers that may lead to medication rationing or dose skipping.

Sanofi (NYSE:SNY) has partnered with celebrity mothers including Mandy Moore and other influential personalities to promote BEYFORTUS®, their RSV prevention treatment for infants. BEYFORTUS is the first long-acting monoclonal antibody approved to prevent serious RSV lung infections in babies up to 24 months old.

The campaign highlights that BEYFORTUS is designed for all babies, regardless of their health status or birth timing. The treatment has demonstrated its safety and effectiveness through clinical studies and over 50 real-world studies involving more than 400,000 babies. RSV is currently the leading cause of hospitalization in infants under one year old.

The initiative features personal stories from celebrity mothers who chose BEYFORTUS for their children, emphasizing its position as the #1 doctor-prescribed choice for RSV protection in infants.

Sanofi (NYSE:SNY) collaborated with the National Association of CHWs (NACHW), NationSwell, and Atlas Clarity to publish a new report titled "Strengthening Public Health with Community Health Workers" during National CHW Awareness Week.

The report highlights the critical role of Community Health Workers (CHWs) in bridging gaps between health services and communities, particularly in rural and underserved areas where over 76 million Americans live in Health Professional Shortage Areas. The study emphasizes successful programs where CHWs are engaged early in program design, properly compensated, and integrated effectively into care teams.

Key recommendations include partnering with CHW Networks on policy priorities, creating permanent roles for CHWs, and investing in quantifying their impact on specific diseases and ROI. The full report is available at www.nachw.org/projects/strengthening-ph-chws/.

Sanofi (NYSE:SNY) announced groundbreaking real-world study results for BEYFORTUS®, showing an 87% reduction in RSV disease cases across all care sites among healthy, term babies. The largest US real-world study demonstrated a remarkable 98% reduction in RSV hospitalizations compared to untreated infants.

The study, published in PEDIATRICS®, successfully met both co-primary endpoints. Beyond disease prevention, BEYFORTUS-treated infants who contracted RSV showed significantly fewer medical visits. The research included over 30,000 healthy, full-term babies, supporting previous findings from pivotal trials where BEYFORTUS showed 74.9% and 70.1% relative risk reductions in serious RSV disease.

Sanofi (NASDAQ:SNY) has launched its inaugural Healthy Futures Solution Fund, awarding over $1 million in grants to support Massachusetts-based nonprofits. The initiative aims to improve health equity and access to healthcare in historically undersupported communities.

The fund will support 14 nonprofit organizations including Boston Health Care for the Homeless, Boston Children's Hospital Trust, and Community Servings, focusing on addressing social drivers of health such as housing, food security, and behavioral health. The funding period extends through June 2026, after which organizations will submit impact reports detailing measurable outcomes.

Sanofi has agreed to acquire Blueprint Medicines for $129.00 per share in cash ($9.1B total), plus potential CVR payments worth up to $6 per share, bringing the total potential value to $9.5B. The acquisition centers on Blueprint's Ayvakit/Ayvakyt, the only approved medicine for advanced and indolent systemic mastocytosis (SM), a rare immunological disease. Ayvakit generated $479M in revenue in 2024 and showed 60% YoY growth in Q1 2025. The deal includes Blueprint's pipeline assets: elenestinib (Phase 2/3 for SM) and BLU-808 (early-stage KIT inhibitor). The transaction represents a 27% premium to Blueprint's closing price and is expected to close in Q3 2025. The acquisition will be immediately accretive to gross margin and accretive to business operating income and EPS after 2026.

Sanofi (SNY) has unveiled its new $130 million flagship US offices in Morristown, New Jersey, marking a significant expansion of its US presence. The 260,000-square-foot facility will accommodate nearly 2,000 employees and features state-of-the-art design elements focused on collaboration and innovation. The building is designed to achieve LEED Gold Certification and WELL Gold Building standards, with impressive sustainability metrics including 28% less energy usage and 24% reduced greenhouse gas emissions compared to standard offices. The facility offers modern amenities, including flexible workspaces, wellness rooms, a public restaurant, and New Jersey's largest outdoor terrace space. As part of its community commitment, Sanofi announced support for the Zufall Health Center and joined the Meal Recovery Coalition to address food insecurity in New Jersey.